A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy

ClinicalTrials.gov processed this data on June 28, 2024. Link to the current ClinicalTrials.gov record.

Recruitment Status

ACTIVE, NOT RECRUITING (See Contacts and Locations)
Verified June 2024 by Janssen Research & Development, LLC

Sponsor

Janssen Research & Development, LLC

Information Provided by (Responsible Party)

Janssen Research & Development, LLC

Clinicaltrials.gov Identifier

NCT05388669
Other Study ID Numbers: CR109211
First Submitted: May 19, 2022
First Posted: May 24, 2022
Last Update Posted: July 3, 2024
Last Verified: June 2024
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

Not Provided
Condition or Disease Intervention/Treatment
  • Advanced or Metastatic Non-small Cell Lung Cancer
  • Drug: Lazertinib
  • Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
  • Drug: Amivantamab Intravenous

Study Design

Study TypeInterventional
Actual Enrollment418 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleA Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy
Study Start DateAugust 5, 2022
Actual Primary Completion DateJanuary 3, 2024
Anticipated Study Completion DateJanuary 9, 2025

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • Arm A: Lazertinib with Amivantamab SC-CF
    • Lazertinib 240 milligrams (mg) will be administered orally once daily. Participants will receive amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), 1600 mg/ 2240 mg depending on the body weight by manual injection. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the long-term extension (LTE) Phase.
  • Drug: Lazertinib
    • Lazertinib tablets will be administered orally.
  • Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
    • Arm B: Lazertinib with Amivantamab Intravenous (IV) Infusion
      • Lazertinib 240 mg will be administered orally once. Participants will receive amivantamab, 1050 mg or 1400 mg depending on the body weight as an IV infusion. Participants benefiting from study treatment after primary analysis may continue to receive access to study treatment within the study by transferring to the LTE Phase.
    • Drug: Lazertinib
      • Lazertinib tablets will be administered orally.
    • Drug: Amivantamab Intravenous

      Outcome Measures

      Primary Outcome Measures

      1. For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State on Cycle 4 Day 1 [Cycle 4 Day 1 (28 days cycle)]
        Ctrough is the observed serum concentration of Amivantamab at steady state on Cycle 4 Day 1 immediately prior to the next drug administration.
      2. For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab at Pre-dose on Cycle 2 Day 1 [Cycle 2 Day 1 (28 days cycle)]
        Ctrough is the observed serum concentration of Amivantamab at pre-dose on Cycle 2 Day 1 immediately prior to the next drug administration.
      3. Area Under the Concentration Time Curve from Day 1 to Day 15 (AUC[Day 1-15]) of Amivantamab of Cycle 2 [Cycle 2 Day 1 to Cycle 2 Day 15 (28 days cycle)]
        AUC(Day 1-15) defined as area under the concentration time curve from Cycle 2 Day 1 to Day 15, will be reported.

      Secondary Outcome Measures

      1. Objective Response Rate (ORR) [Up to 1 year 11 months]
        ORR is defined as the percentage of participants who achieve either a CR or PR as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST version 1.1).
      2. Progression-Free Survival (PFS) [Up to 1 year 11 months]
        PFS is defined as the time from randomization until the date of objective disease progression or death, whichever comes first, based on RECIST version 1.1.
      3. Duration of Response (DOR) [Up to 1 year 11 months]
        The DoR is defined as the time from the date of first documented response (PR or CR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR.
      4. Time to Response (TTR) [Up to 1 year 11 months]
        Time to response (that is time to first response) is defined as the time from the date of randomization to the date of first documentation of a response (PR or CR) prior to any disease progression and subsequent anticancer therapy, as defined by BICR using RECIST version 1.1., for participants who have PR or CR as their best response.
      5. Number of Participants With Adverse Events (AEs) [Up to 4 year 11 months]
        An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. This outcome includes participants continuing in the LTE Phase for whom, after the primary analysis, data were collected until a discontinuation criterion is met, or until 3 years after local marketing authorization is obtained.
      6. Number of Participants with AEs by Severity [Up to 4 year 11 months]
        Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. This outcome includes participants continuing in the LTE Phase for whom, after the primary analysis, data were collected until a discontinuation criterion is met, or until 3 years after local marketing authorization is obtained.
      7. Number of Participants with Clinical Laboratory Abnormalities [Up to 4 year 11 months]
        Number of participants with clinical laboratory abnormalities (serum Chemistry, hematology, coagulation, and urinalysis) will be reported. This outcome includes participants continuing in the LTE Phase for whom, after the primary analysis, data were collected until a discontinuation criterion is met, or until 3 years after local marketing authorization is obtained.
      8. Number of Participants with Clinical Laboratory Abnormalities by Severity [Up to 4 year 11 months]
        Number of participants with clinical laboratory abnormalities by severity (serum Chemistry, hematology, coagulation, and urinalysis) will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. This outcome includes participants continuing in the LTE Phase for whom, after the primary analysis, data were collected until a discontinuation criterion is met, or until 3 years after local marketing authorization is obtained.
      9. Number of Participants Infusion Related Reactions (IRRs) [Up to 1 year 11 months]
        Number of participants with IRRs will be reported.
      10. Number of Participants with Infusion Related Reactions (IRRs) by Severity [Up to 1 year 11 months]
        Number of participants with IRRs by severity will be reported.
      11. For All Regions Other Than the EU and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Pre-dose on Cycle 2 Day 1 [Cycle 2 Day 1 (28 days cycle)]
        The Ctrough is the observed serum concentration of Amivantamab at pre-dose on Cycle 2 Day 1 immediately prior to the next drug administration.
      12. For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State on Cycle 4 Day 1 [Cycle 4 Day 1 (28 days cycle)]
        The Ctrough is the observed serum concentration of Amivantamab at steady state on Cycle 4 Day 1 immediately prior to the next drug administration.
      13. Model-Predicted Area Under the Concentration Time Curve from Day 1 to Day 15 (AUC[Day 1-15]) of Amivantamab at Steady State of Cycle 4 [From Cycle 4 Day 1 to Cycle 4 Day 15 (28 days cycle)]
        Model-predicted AUC(Day 1-15) defined as area under the concentration time curve from Cycle 4 Day 1 to Day 15, will be reported.
      14. Percentage of Participants with Presence of Anti-amivantamab Antibodies and Anti-rHuPH20 Antibodies [Up to 1 year 11 months]
        Percentage of participants with presence of anti-amivantamab antibody anti-rHuPH20 antibodies will be reported.
      15. Percentage of Participants with Cancer Therapy Satisfaction as Assessed by Therapy Administration Satisfaction Questionnaire (TASQ) [Up to 1 year 11 months]
        Percentage of participants with cancer therapy satisfaction in will be assessed using the modified TASQ. The modified TASQ is an 11-item questionnaire measuring the impact of each mode of treatment administration on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction.
      16. Change from Baseline in TASQ as Assessed Over Time [Up to 1 year 11 months]
        Change from baseline in TASQ as assessed Over time will be reported. The modified TASQ is an 11-item questionnaire measuring the impact of each mode of treatment administration on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction.
      17. Participant Chair Time [Up to 1 year 11 months]
        Participant chair time will be assessed by time and motion analysis.
      18. Duration of Treatment Administration [Up to 1 year 11 months]
        Duration of treatment administration will be assessed by time and motion analysis.
      19. Active HCP Time For Drug Preparation, Treatment Administration and Posttreatment Monitoring [Up to 1 year 11 months]
        Active health care professional time for drug preparation, treatment administration, and posttreatment monitoring will be assessed by time and motion analysis.
      20. Participant Time in Treatment Room [Up to 1 year 11 months]
        Participant time in treatment room will be assessed by time and motion analysis.

      Eligibility Criteria

      Ages Eligible for Study 18 Years and Older (Adult, Older Adult)
      Sexes Eligible for Study All
      Accepts Healthy Volunteers No
      Inclusion Criteria
      • Have histologically or cytologically confirmed, advanced or metastatic non-small cell lung cancer (NSCLC), characterized by either epidermal growth factor receptor (EGFR) Exon 19 deletion (Exon 19del) or Exon 21 leucine 858 to arginine substitution (Exon 21 L858R) mutation by an Food and Drug Administration (FDA)-approved or other validated test of either circulating tumor deoxyribonucleic acid (ctDNA) or tumor tissue in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United Started [US]) or an accredited local laboratory (sites outside of the US)
      • Have progressed on or after osimertinib (or another approved 3rd generation epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor [TKI]) and platinum-based chemotherapy (irrespective of order). a) The 3rd generation EGFR TKI must have been administered as the first EGFR TKI for metastatic disease or as the second TKI after prior treatment with first- or second-generation EGFR TKI in participants with metastatic EGFR T790M mutation positive NSCLC. b) Participants who decline or are otherwise ineligible for chemotherapy may be enrolled after discussion with the medical monitor. c) Any adjuvant or neoadjuvant treatment, whether with a 3rd generation EGFR TKI or platinum based chemotherapy, would count towards the prior treatment requirement if the participant experienced disease
      • Have at least 1 measurable lesion, according to response evaluation criteria in solid tumors (RECIST) version 1.1
      • Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
      • Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Version 5.0 Grade 1 or baseline level (except for alopecia [any grade], Grade less than or equal to (<=) 2 peripheral neuropathy, and Grade <=2 hypothyroidism stable on hormone replacement)
      Exclusion Criteria
      • Participant has received cytotoxic, investigational, or targeted therapies beyond one regimen of platinum-based chemotherapy and EGFR inhibitors
      • Participant has received radiotherapy for palliative purposes less than 7 days prior to randomization
      • Participant has symptomatic or progressive brain metastases
      • Participant has leptomeningeal disease, or participant has spinal cord compression not definitively treated with surgery or radiation
      • Participant has uncontrolled tumor-related pain
      • Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis

      Contacts and Locations

      Sponsors and Collaborators Janssen Research & Development, LLC
      Locations
      • City of Hope Duarte | Duarte, California, United States, 91010
      • City of Hope Orange County Lennar Foundation Cancer Center | Irvine, California, United States, 92618
      • City of Hope Long Beach Elm | Long Beach, California, United States, 90813
      • National Jewish Health | Denver, Colorado, United States, 80206
      • Baptist Lynn Cancer Institute | Boca Raton, Florida, United States, 33486
      • Orlando Health | Orlando, Florida, United States, 32806
      • University of Kansas | Kansas City, Kansas, United States, 66160
      • University of Michigan | Ann Arbor, Michigan, United States, 48109
      • Astera Cancer Care | East Brunswick, New Jersey, United States, 08816
      • Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States, 08901
      • Montefiore Medical Center | Bronx, New York, United States, 10461
      • NYU Langone Health Laura and Isaac Perlmutter Cancer Center | New York, New York, United States, 10016
      • Providence Portland Medical Center | Portland, Oregon, United States, 97213
      • Providence Oncology and Hematology Care Clinic Westside | Portland, Oregon, United States, 97225
      • University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine | Philadelphia, Pennsylvania, United States, 19104
      • Medical University of South Carolina | Charleston, South Carolina, United States, 29425
      • Virginia Cancer Specialists | Fairfax, Virginia, United States, 22031
      • CEMIC (Centro de Educación Médica e Investigaciones Clínicas) | Buenos Aires, Argentina, 1431
      • IADT Instituto Argentino de Diagnostico y Tratamiento | Caba, Argentina, C1122
      • Centro Oncológico Korben | Ciudad Autonoma de Buenos Aires, Argentina, C1426AGE
      • Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica | Cordoba, Argentina, 5000
      • Sanatorio Allende | Cordoba, Argentina, 5000
      • Clínica Viedma | Viedma, Argentina, R8500ACE
      • Cancer Research SA | Adelaide, Australia, 5000
      • Chris O'Brien Lifehouse | Camperdown, Australia, 2050
      • Peter MacCallum Cancer Centre | Melbourne, Australia, 3000
      • St John of God Hospital Murdoch | Murdoch, Australia, 6150
      • Westmead Hospital | Westmead, Australia, 2145
      • Princess Alexandra Hospital | Woolloongabba, Australia, 4102
      • Fundacao Pio XII | Barretos, Brazil, 14784-400
      • Cetus Oncologia | Belo Horizonte, Brazil, 30110-017
      • Instituto Cionc de Ensino e Pesquisa S/S | Curitiba, Brazil, 80810-050
      • Ynova Pesquisa Clinica | Florianopolis, Brazil, 88020-210
      • Fundacao Sao Francisco Xavier HMC Unidade de Oncologia | Ipatinga, Brazil, 35162 189
      • UPCO Unidade de Pesquisa Clinica em Oncologia | Pelotas, Brazil, 96020 080
      • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS | Porto Alegre, Brazil, 90610-000
      • Impar Servicos Hospitalares S/A | Rio de Janeiro, Brazil, 22061-080
      • Oncoclinicas Rio de Janeiro S A | Rio de Janeiro, Brazil, 22250 905
      • Instituto D Or de Pesquisa e Ensino (IDOR) | Rio de Janeiro, Brazil, 22281 100
      • Nucleo de Oncologia da Bahia | Salvador, Brazil, 40170 110
      • CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia | Santo Andre, Brazil, 09060-650
      • Impar Servicos Hospitalares SA - Hospital Nove de Julho | Sao Paulo, Brazil, 01409-002
      • Núcleo de Pesquisa São Camilo | São Paulo, Brazil, 04014-002
      • Onco Star SP Oncologia Ltda | São Paulo, Brazil, 04543-000
      • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein | São Paulo, Brazil, 05652-900
      • The Ottawa Hospital Cancer Centre | Ottawa, Ontario, Canada, K1H 8L6
      • Princess Margaret Hospital | Toronto, Ontario, Canada, M5G 1Z5
      • Beijing Shijitan Hospital, Capital Medical University | Beijing, China, 100038
      • Beijing Friendship Hospital Capital Medical University | Beijing, China, 100050
      • Peking University Third Hospital | Beijing, China, 100191
      • Beijing Chest hospital, Capital medical university | Beijing, China, 101149
      • Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China, 200240
      • Jilin cancer hospital | Changchun, China, 130012
      • The First People's Hospital Of Changzhou | Changzhou, China, 213004
      • Sichuan Cancer Hospital | Chengdu, China, 610041
      • West China Hospital Sichuan University | Chengdu, China, 610047
      • Chongqing University Cancer Hospital | Chongqing, China, 400030
      • Southwest Hospital | ChongQing, China, 400038
      • First Affiliated Hospital of Gannan Medical University | Ganzhou, China, 341000
      • The First Affiliated Hospital Sun Yat sen University | Guang Zhou, China, 510080
      • Sun Yat-Sen Memorial Hospital Sun Yat-sen University | Guangzhou, China, 510000
      • Zhejiang Cancer Hospital | Hang Zhou, China, 310022
      • The Second Affiliated Hospital of Zhejiang University College of Medicine | Hangzhou, China, 310009
      • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Hangzhou, China, 310016
      • Harbin medical university cancer hospital | Harbin, China, 150081
      • Huizhou Municipal Central Hospital | Huizhou, China, 516001
      • Huizhou First Hospital | Huizhou, China, 516003
      • Liuzhou people's Hospital | Liuzhou, China, 545026
      • Affiliated Hospital of North Sichuan Medical College | Nanchong, China, 637100
      • Fudan University Shanghai Cancer Center | Shanghai, China, 200032
      • Shenzhen People s Hospital | Shen Zhen Shi, China, 518001
      • Shengjing Hospital Of China Medical University | Shenyang, China, 110004
      • Shenzhen university General Hospital | Shenzhen, China, 518055
      • Tianjin Medical University Cancer Institute and Hospital | Tianjin, China, 300060
      • Union Hospital Tongji Medical College of Huazhong University of Science and Technology | Wuhan, China, 430022
      • The First Affiliated Hospital of Xian Jiaotong University | XI An, China, 710061
      • Xiangyang Central Hospital | Xiangyang, China, 441021
      • Yantai Yuhuangding Hospital | Yantai, China, 264000
      • Henan Cancer Hospital | Zhengzhou, China, 450008
      • CHU Grenoble | La Tronche, France, 38700
      • Institute Coeur Poumon | Lille, France, 59000
      • CHU de Limoges Hopital Dupuytren | Limoges, France, 87000
      • Hopital Nord | Marseille Cedex 20, France, 13915
      • Evangelische Lungenklinik Berlin | Berlin, Germany, 13125
      • Niels-Stensen-Kliniken Franziskus-Hospital Harderberg | Georgsmarienhütte, Germany, 49124
      • Universitaetsklinikum Giessen und Marburg GmbH | Giessen, Germany, 35392
      • Munster University Hospital | Münster, Germany, 48149
      • Oncologianova GmbH | Recklinghausen, Germany, 45659
      • Onkologische Schwerpunktpraxis | Weinsberg, Germany, 74189
      • Rambam Medical Center | Haifa, Israel, 3109601
      • Shaare Zedek Medical Center | Jerusalem, Israel, 91031
      • Meir Medical Center | Kfar Saba, Israel, 44281
      • Rabin Medical Center | Petah-Tikva, Israel, 49100
      • Chaim Sheba Medical Center | Ramat Gan, Israel, 5262100
      • Oncologia Medica - Irccs - Istituto Tumori Giovanni Paolo II | Bari, Italy, 70124
      • A O U Sant Orsola Malpighi | Bologna, Italy, 40138
      • European Institute of Oncology | Milano, Italy, 20141
      • Aou San Luigi Gonzaga | Orbassano, Italy, 10043
      • Istituto Oncologico Veneto - IRCCS | Padova, Italy, 35128
      • Ospedale S. Maria Delle Croci | Ravenna, Italy, 48121
      • A.O. San Camillo Forlanini | Roma, Italy, 00152
      • Istituto Nazionale Tumori Regina Elena | Rome, Italy, 00144
      • Istituto Clinico Humanitas | Rozzano, Italy, 20089
      • National Cancer Center Hospital | Chuo Ku, Japan, 104 0045
      • National Hospital Organization Himeji Medical Center | Himeji, Japan, 670-8520
      • Kansai Medical University Hospital | Hirakata, Japan, 573-1191
      • Kanagawa Cancer Center | Kanagawa, Japan, 241-8515
      • Kurashiki Central Hospital | Kurashiki, Japan, 710-8602
      • Kurume University Hospital | Kurume, Japan, 830-0011
      • Matsusaka Municipal Hospital | Matsusaka, Japan, 515-8544
      • Niigata Cancer Center Hospital | Niigata, Japan, 951-8566
      • Okayama University Hospital | Okayama, Japan, 700-8558
      • Osaka International Cancer Institute | Osaka, Japan, 541-8567
      • Hokkaido University Hospital | Sapporo-shi, Japan, 060-8648
      • Shizuoka Cancer Center | Shizuoka, Japan, 411 8777
      • The Cancer Institute Hospital of JFCR | Tokyo, Japan, 135 8550
      • Fujita Health University Hospital | Toyoake, Japan, 470-1192
      • National Hospital Organization Osaka Toneyama Medical Center | Toyonaka-shi, Japan, 560-8552
      • Wakayama Medical University Hospital | Wakayama, Japan, 641 8510
      • National Hospital Organization Iwakuni Clinical Center | Yamaguchi, Japan, 740-8510
      • National Hospital Organization Yamaguchi Ube Medical Center | Yamaguchi, Japan, 755-0241
      • National Cancer Center | Gyeonggi-do, Korea, Republic of, 10408
      • CHA Bundang Medical Center, CHA University | Gyeonggi-do, Korea, Republic of, 13496
      • GyeongSang National University Hospital | Gyeongsangnam-do, Korea, Republic of, 52727
      • Chonnam National University Hwasun Hospital | Jeollanam-do, Korea, Republic of, 58128
      • Seoul National University Bundang Hospital | Seongnam-si, Korea, Republic of, 13620
      • Seoul National University Hospital | Seoul, Korea, Republic of, 03080
      • Severance Hospital Yonsei University Health System | Seoul, Korea, Republic of, 03722
      • Asan Medical Center | Seoul, Korea, Republic of, 05505
      • Samsung Medical Center | Seoul, Korea, Republic of, 06351
      • Prince Court Medical Centre | Kuala Lumpur, Malaysia, 50450
      • Pantai Hospital Kuala Lumpur | Kuala Lumpur, Malaysia, 59100
      • University Malaya Medical Centre | Kuala Lumpur, Malaysia, 59100
      • Hospital Umum Sarawak | Kuching, Malaysia, 93586
      • Beacon Hospital Sdn Bhd | Petaling Jaya, Malaysia, 46050
      • Sunway Medical Centre | Petaling Jaya, Malaysia, 47500
      • Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy | Bydgoszcz, Poland, 85-796
      • Krakowski Szpital Specjalityczny im. Jana Pawla II | Krakow, Poland, 31-202
      • Mazowieckie Centrum Leczenia Chorob Pluc | Otwock, Poland, 05-400
      • Private Specialist Hospitals - MedPolonia | Poznan, Poland, 60-693
      • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy | Warszawa, Poland, 02-781
      • Hospital de Braga | Braga, Portugal, 4710-243
      • Hospital da Luz, SA | Lisboa, Portugal, 1500-650
      • Hosp. Cuf Descobertas | Lisboa, Portugal, 1998-018
      • Hospital Pedro Hispano | Senhora da Hora,, Portugal, 4464-513
      • Hosp. Univ. A Coruna | A Coruna, Spain, 15006
      • Hosp. Gral. Univ. de Alicante | Alicante, Spain, 03010
      • Hosp. Univ. Vall D Hebron | Barcelona, Spain, 08035
      • Hosp. Clinic de Barcelona | Barcelona, Spain, 08036
      • Hosp. Univ. Quiron Dexeus | Barcelona, Spain, 8028
      • Hosp. Reina Sofia | Córdoba, Spain, 14004
      • Hosp. Univ. Insular de Gran Canaria | Las Palmas de Gran Canaria, Spain, 35016
      • Hosp. Univ. Lucus Augusti | Lugo, Spain, 27003
      • Hosp. Gral. Univ. Gregorio Maranon | Madrid, Spain, 28009
      • Hosp. Univ. La Paz | Madrid, Spain, 28046
      • Hosp. Univ. Pta. de Hierro Majadahonda | Majadahonda, Spain, 28222
      • Hosp. Regional Univ. de Malaga | Málaga, Spain, 29011
      • Hosp. Univ. Central de Asturias | Oviedo, Spain, 33011
      • Hosp. Univ. Son Espases | Palma de Mallorca, Spain, 07120
      • Hosp. Virgen Del Rocio | Sevilla, Spain, 41013
      • Hosp. Univ. I Politecni La Fe | Valencia, Spain, 46026
      • Changhua Christian Hospital | Changhua, Taiwan, 50006
      • Chang Kung Memorial Hospital | Kaohsiung City, Taiwan, 833
      • Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung, Taiwan, 80756
      • Chung Shan Medical University Hospital | Taichung, Taiwan, 403
      • National Cheng Kung University Hospital | Tainan, Taiwan, 70403
      • National Taiwan University Cancer Center | Taipei City, Taiwan, 106
      • National Taiwan University Hospital | Taipei, Taiwan, 10048
      • Linkou Chang Gung Memorial Hospital | Taoyuan, Taiwan, 33382
      • Phramongkutklao Hospital and Medical College | Bangkok, Thailand, 10400
      • Siriraj Hospital | Bangkok, Thailand, 10700
      • Chiang Mai University | Chiangmai, Thailand, 50200
      • Adana City Hospital | Adana, Turkey, 01060
      • Adana Baskent Hospital | Adana, Turkey, 01120
      • Memorial Ankara Hastanesi | Ankara, Turkey, 06520
      • Gazi University Hospital | Ankara, Turkey, 06560
      • Ankara Bilkent City Hospital | Ankara, Turkey, 06800
      • Trakya University Medical Faculty | Edirne, Turkey, 22030
      • Istanbul University Cerrahpasa Medical Faculty | Istanbul, Turkey, 34098
      • Acıbadem Maslak Hospital | Istanbul, Turkey, 34457
      • Dokuz Eylul University Medical Faculty | Izmir, Turkey, 35330
      • IEU Medical Point Hospital | Izmir, Turkey, 35575
      • Medical Park Samsun Hastanesi | Samsun, Turkey, 55200
      • Birmingham Heartlands Hospital | Birmingham, United Kingdom, B9 5SS
      • Imperial College Healthcare | London, United Kingdom, W2 1NY
      • Newcastle Freeman Hospital | Newcastle Upon Tyne, United Kingdom, NE7 7DN
      • Royal Marsden Hospital | Sutton, United Kingdom, SM2 5PT
      Investigators

        More Information

        Additional Relevant MeSH Terms

        • Lung Neoplasms
        • Carcinoma, Non-Small-Cell Lung
        • Respiratory Tract Neoplasms
        • Thoracic Neoplasms
        • Neoplasms by Site
        • Neoplasms
        • Lung Diseases
        • Respiratory Tract Diseases
        • Carcinoma, Bronchogenic
        • Bronchial Neoplasms